Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 501–600 of 1,002
Negative Feedback Regulation of IFN-γ Pathway by IFN Regulatory Factor 2 in Esophageal Cancers
Wang, Y., Liu, D., Chen, P., Koeffler, H. P., Tong, X., & Xie, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5021 · Cited by 60
“Although the results seemed largely contrary to the general conception that IFN-g functions as an antitumor cytokine (8, 28, 29), some researches have reported that IFN-g also possesses the activity to promote cell growth under some conditions (30–36).”
ResultDendritic cells and innate defense against tumor cells
Ullrich, E., Menard, C., Flament, C., Terme, M., Mignot, G., Bonmort, M., Plumas, J., Chaperot, L., Chaput, N., & Zitvogel, L. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.009 · Cited by 57
Marozin, S., Altomonte, J., Stadler, F. J., Thasler, W. E., Schmid, R. M., & Ebert, O. (2008) · Molecular Therapy · doi:10.1038/mt.2008.201 · Cited by 53
Salimu, J., Spary, L. K., Al‐Taei, S., Clayton, A., Mason, M. D., Staffurth, J. N., & Tabi, Z. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0079 · Cited by 53
Zou, Q., Jin, J., Xiao, Y., Zhou, X., Hu, H., Cheng, X., Kazimi, N., Ullrich, S. E., & Sun, S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.046 · Cited by 57
“Interferon-g (IFN-g), produced by effector T cells and innate immune cells, is known as a cytokine that promotes innate and adaptive immune responses against microbial infections and tumor development (Dunn et al., 2006).”
Coleman, O. I., & Nunes, T. (2016) · BioResearch open access · doi:10.1089/biores.2016.0028 · Cited by 55
“plastic responses, whereas TH17 contributes to tumorigenic responses.(26,43,44) In this regard, Wu et al.”
BackgroundFusogenic Viruses in Oncolytic Immunotherapy
Krabbe, T., & Altomonte, J. (2018) · Cancers · doi:10.3390/cancers10070216 · Cited by 53
Xiao, X., Liang, J., Huang, C., Li, K., Xing, F., Zhu, W., Lin, Z., Xu, W., Wu, G., Zhang, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06771-4 · Cited by 53
RetractedThe Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway
Martín-Hijano, L., & Sáinz, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00526 · Cited by 57
“Finally and more interestingly, the concept of immunoediting might prove beneficial to further explain the contradictory conclusions regarding the effect of IFNs on CSCs (196) (Figure 2) (Table 1).”
BackgroundPatutina, O., Mironova, N. L., Ryabchikova, E. I., Popova, N. A., Nikolin, V. P., Kaledin, V. I., Vlassov, V. V., & Аркадьевна, З. М. (2010) · Biochimie · doi:10.1016/j.biochi.2010.12.011 · Cited by 55
Soypeptide lunasin in cytokine immunotherapy for lymphoma
Chang, H., Lewis, D., Tung, C.-Y., Han, L., Henriquez, S. M. P., Voiles, L., Lupov, I. P., Pelloso, D., Sinn, A. L., Pollok, K. E., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1513-8 · Cited by 58
“However, administration of recombinant IFNγ had disappointing outcomes in various cancer immunotherapy trials possibly due to its toxicity [8].”
BackgroundMechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 56
“Through multiple pathways, IFN can ultimately exert anti-tumor immune effects by increasing intrinsic and adaptive immune cell functions, and IFN mainly induces intracellular changes through the JAK/STAT pathway (84).”
BackgroundAdenoviral vector-mediated gene therapy for gliomas: coming of age
Castro, M. G., Candolfi, M., Wilson, T. J., Calinescu, A., Paran, C. W., Kamran, N., Koschmann, C. J., Moreno-Ayala, M. A., Assi, H. H., & Lowenstein, P. R. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.915307 · Cited by 56
“Since then, other tumor models have confirmed the importance of IFN-g in controlling tumor growth [73].”
BackgroundResultThe Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats
Shenoy, P. A., Kuo, A., Vetter, I., & Smith, M. T. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00286 · Cited by 55
“…and Topalian, 1998; Rees and Mian, 1999), differential propagation of tumor sub clones in their microenvironment (Khong and Restifo, 2002) and consequent elimination by immune cells, antibodies, cytokines, and chemokines (Dunn et al., 2002, 2006; Bui and Schreiber, 2007; Jaganjac et al., 2008).”
BackgroundThe Janus Face of Death Receptor Signaling during Tumor Immunoediting
Reilly, E. O., Tirincsi, A., Logue, S. E., & Szegezdi, É. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00446 · Cited by 58
“The tumor immune suppression may however break or become exhausted, allowing unrestricted growth of the tumor cells (escape phase) (64, 65).”
BackgroundXu, Y., Li, Z.-L., & Qiu, S. (2018) · Translational Oncology · doi:10.1016/j.tranon.2017.11.008 · Cited by 52
“IFN-γ, a cytokine that is critical for innate and adaptive immunity, is secreted by activated effector T cells [30].”
BackgroundChen, Y., Hao, X., Sun, R., Wei, H., & Tian, Z. (2019) · Hepatology · doi:10.1002/hep.30317 · Cited by 55
“(13,14) Further, IFN-γ participates in cancer elimination (immunosurveillance), protecting mice against chemically induced, spontaneous, and transplantable tumors.(15,16) IFN-γ suppresses diethylnitrosamine (DEN)–induced chemical hepatocarcinogenesis, partly by its known immune activating function of infiltrating clus…”
BackgroundThe Identification of Immunological Biomarkers in Kidney Cancers
López-Beltrán, A., Henriques, V., Cimadamore, A., Santoni, M., Cheng, L., Gevaert, T., Blanca, A., Massari, F., Scarpelli, M., & Montironi, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00456 · Cited by 56
Shi, R., Zhao, K., Wang, T., Yuan, J., Zhang, D., Xiang, W., Qian, J., Luo, N., Zhou, Y., Tang, B., et al. (2021) · Theranostics · doi:10.7150/thno.66420 · Cited by 53
“Based on its pro-apoptotic and anti-proliferative functions, IFNγ is considered to have potential adjuvant immunotherapeutic effects on different types of cancer [26].”
BackgroundFunctional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity
Göbel, C., Breitenbuecher, F., Kalkavan, H., Hähnel, P. S., Kasper, S., Hoffarth, S., Merches, K., Schild, H., Lang, K. S., & Schuler, M. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.531 · Cited by 46
The interferon-dependent orchestration of innate and adaptive immunity after transplantation
Robb, R. J., & Hill, G. R. (2012) · Blood · doi:10.1182/blood-2012-02-368076 · Cited by 50
Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer
Goodman, M. L., Trinca, G. M., Walter, K. R., Papachristou, E. K., D’Santos, C. S., Li, T., Liu, Q., Lai, Z., Chalise, P., Madan, R., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801152 · Cited by 54
Baltz, K. M., Krusch, M., Baessler, T., Schmiedel, B. J., Bringmann, A., Brossart, P., & Salih, H. R. (2008) · Blood · doi:10.1182/blood-2008-03-143016 · Cited by 54
Exploiting antitumor immunity to overcome relapse and improve remission duration
Chen, L. L., Chen, X., Choi, H., Sang, H., Chen, L. C., Zhang, H., Gouw, L. G., Andtbacka, R. H. I., Chan, B. K., Rodesch, C. K., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1185-1 · Cited by 52
“Dendritic cells (DCs) capture, process, and cross-present antigens in the context of MHC class-I and costimulatory molecules to subsets of T-lymphocytes, and play critical roles in the regulation and development of distinct immune responses [8–10] including (1) Th1 adaptive cell-mediated immunity (Th1 response) signif…”
BackgroundInfluentialIn vivo tumor suppression activity by T cell‐specific T‐bet restoration
Lee, K., Min, H. J., Jang, E. J., Hong, J., & Hwang, E. S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25238 · Cited by 53
Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
Ni, Y., Low, J. T., Silke, J., & O’Reilly, L. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835997 · Cited by 54
Deng, Y., Chu, J., Ren, Y., Fan, Z., Ji, X., Mundy-Bosse, B. L., Yuan, S., Hughes, T. L., Zhang, J., Cheema, B. S., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302600 · Cited by 56
Tumor cell recognition by the NK cell activating receptor NKG2D
Bryceson, Y. T., & Ljunggren, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838833 · Cited by 53
Fujita, K., Ewing, C. M., Isaacs, W. B., & Pavlovich, C. P. (2010) · International Journal of Cancer · doi:10.1002/ijc.25705 · Cited by 52
“IFN-c is produced by NK cells, NKT cells and T cells upon IL-12 and IL-18 stimulation; the antitumor effect of IFN-c has been observed in many animal models.(18,19) IFN-c can exert both direct antiproliferative and antimetabolic effects on tumor cells, and inhibit angiogenesis within a tumor.”
BackgroundMapping the p53 transcriptome universe using p53 natural polymorphs
Wang, B., Niu, D., Lam, T. H., Xiao, Z., & Ren, E. C. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.132 · Cited by 52
Thomas, D., Doty, R. A., Tosic, V., Liu, J., Kranz, D. M., McFadden, G., MacNeill, A. L., & Roy, E. J. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1045-z · Cited by 51
Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts
Yang, L., Forker, L. J., Irlam, J. J., Pillay, N., Choudhury, A., & West, C. (2017) · Oncotarget · doi:10.18632/oncotarget.23280 · Cited by 51
“Interferon signaling proteins have important functions in initializing immune response and activing immune cells [22].”
BackgroundMalignancy and IFITM3: Friend or Foe?
Rajapaksa, U., Chen, J., & Dong, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593245 · Cited by 52
“IFNs have a complex and dynamic role in cancer immune responses and treatment success (89).”
BackgroundPivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis
Zhang, C., Dang, D., Cong, L., Sun, H., & Cong, X. (2021) · Cancer Medicine · doi:10.1002/cam4.3963 · Cited by 53
Patil, S., Gentschev, I., Nolte, I. J. A., Ogilvie, G., & Szalay, A. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-3 · Cited by 57
“IFNs are a group of secreted cytokines, which exert pleiotropic effects on important cell functions, including cell proliferation and modulation of the immune system [72,73].”
BackgroundIoannou, N., Hagner, P. R., Stokes, M., Gandhi, A. K., Apollonio, B., Fanous, M., Papazoglou, D., Sutton, L., Rosenquist, R., Amini, R., et al. (2020) · Blood · doi:10.1182/blood.2020006073 · Cited by 52
ILC1s control leukemia stem cell fate and limit development of AML
Li, Z., Ma, R., Ma, S., Tian, L., Lu, T., Zhang, J., Mundy-Bosse, B. L., Zhang, B., Marcucci, G., Caligiuri, M. A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01198-y · Cited by 49
Antigen Processing and MHC-II Presentation by Dermal and Tumor-Infiltrating Dendritic Cells
Gerner, M. Y., & Mescher, M. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803479 · Cited by 58
Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages
Tankov, S., Petrovic, M., Lecoultre, M., Espinoza, F. I., Harane, N. E., Bes, V., Chliate, S., Bedoya, D. M., Jordan, O., Borchard, G., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01523-y · Cited by 50
“Nevertheless, innate immune cells are major type I IFN producers that influence cancer immunosur-veillance [47, 48], therefore it is important to understand the cGAS-STING pathway mechanisms in these cells and whether it can be modulated indirectly by factors present in the TME.”
BackgroundDobrzanski, M. J., Rewers‐Felkins, K., Samad, K. A., Quinlin, I. S., Phillips, C. A., Robinson, W., Dobrzanski, D. J., & Wright, S. E. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1128-x · Cited by 50
“Recent studies have shown that IFN-γ can further modulate and facilitate Natural TReg cell subpopulation function and phenotype by induction, conversion, and maintenance of FoxP3 expression in such cells [55–58].”
ResultAntimetastatic Activity of a Preventive Cancer Vaccine
Nanni, P., Nicoletti, G., Palladini, A., Croci, S., Murgo, A., Antognoli, A., Landuzzi, L., Fabbi, M., Ferrini, S., Musiani, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2499 · Cited by 48
“The pleiotropic activities of IFN-g ( 30 ) include direct antitumor effects (antiproliferative activity), indirect effects mediated by secondary chemokines (antiangiogenic activity of MIG and IP-10), and its broad range of activities as an internal regulator of host immune responses (Ig class switch, macrophage activa…”
BackgroundStaphylococcal Superantigens Spark Host-Mediated Danger Signals
Krakauer, T., Pradhan, K., & Stiles, B. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00023 · Cited by 54
“Type II interferon (IFNγ) binds to IFNγR, which belongs to the family of interferon receptors (IFNR), including the structurally different receptors for type I interferons (IFNα, IFNβ) (122, 123).”
BackgroundNK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer
Hoshikawa, M., Aoki, T., Matsushita, H., Karasaki, T., Hosoi, A., Odaira, K., Fujieda, N., Kobayashi, Y., Kambara, K., Ohara, O., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.083 · Cited by 48
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation
Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 55
Hormuth, D. A., Farhat, M., Christenson, C., Curl, B. J., Quarles, C. C., Chung, C. D., & Yankeelov, T. E. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114367 · Cited by 50
Monti, M., Ferrari, G., Gazzurelli, L., Bugatti, M., Facchetti, F., & Vermi, W. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03121-9 · Cited by 48
“Type I IFNs are a class of proinflammatory cytokines (i.e. including 13 genes coding for IFN-α, and individual gene coding for IFN-β, IFN-ω, IFN-ɛ , and IFN-к ) that have context-dependent functions on cancer immunosurveillance and immunoediting [108].”
BackgroundGenomic instability as a driver and suppressor of anti-tumor immunity
Requesens, M., Foijer, F., Nijman, H. W., & de Bruyn, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462496 · Cited by 51
Kübler, K., Pesch, C. T., Gehrke, N., Riemann, S., Daßler, J., Coch, C., Landsberg, J., Wimmenauer, V., Pölcher, M., Rudlowski, C., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201141555 · Cited by 56
IFNβ Produced by TLR4-Activated Tumor Cells Is Involved in Improving the Antitumoral Immune Response
Núñez, N. G., Andreani, V., Crespo, M. I., Nocera, D. A., Breser, M. L., Morón, G., Dejager, L., Libert, C., Rivero, V. E., & Maccioni, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0534 · Cited by 52
“Type I IFNs have an established role in regulating the innate and adaptive arms of the immune system (34, 42-44) and when given exogenously to tumor patients, retard tumor growth and inhibit angiogenesis (34).”
BackgroundQin, Y. W., de Macêdo, M. P., Reuben, A., Forget, M., Haymaker, C., Bernatchez, C., Spencer, C. N., Gopalakrishnan, V., Reddy, S. T., Cooper, Z. A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1321187 · Cited by 47
“Here again, though PD-L1 is suggested to be a resistance and tumor escape mechanism, PD-L1 may be induced as a normal negative feedback mechanism as a result of IFNg production within the tumor microenvironment, commonly produced by infiltrating T cells.(22) This also suggests that UM may not be as responsive to PD-L1…”
BackgroundA Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy
Seya, T., Takeda, Y., & Matsumoto, M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.008 · Cited by 48
Plasmeijer, E. I., Sachse, M. M., Gebhardt, C., Geusau, A., & Bavinck, J. N. B. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16025 · Cited by 47
Chandran, P. A., Keller, A., Weinmann, L., Seida, A. A., Braun, M., Andreev, K., Fischer, B., Horn, E., Schwinn, S., Junker, M., et al. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0114-025r · Cited by 52
Zhang, C., Niu, J., Zhang, J., Wang, Y., Zhou, Z., Zhang, J., & Tian, Z. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00791.x · Cited by 47
Kamphausen, E., Kellert, C., Abbas, T., Akkad, N., Tenzer, S., Pawelec, G., Schild, H., Endert, P. V., & Seliger, B. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0856-7 · Cited by 47
“Human tumours of distinct histologies often exhibit impaired HLA class I surface antigen expression, which is associated with reduced or lack of susceptibility to CTL-mediated lysis, increased metastases formation and poor clinical outcome for the patients [13–17].”
BackgroundSmall cell ovarian carcinoma: genomic stability and responsiveness to therapeutics
Gamwell, L. F., Gambaro, K., Merziotis, M., Crane, C. A., Arcand, S. L., Bourada, V., Davis, C., Squire, J. A., Huntsman, D. D., Tonin, P. N., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-33 · Cited by 51
“This cancer cell selectivity is at least in part due to an acquired, tumour-specific defect in cellular innate antiviral responses [56].”
Zhang, G., Liu, W., Zhang, L., Wang, J., Kuang, M.-H., Liu, P., Lin, Y., Dai, S., & Du, J. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/384726 · Cited by 51
“One suggests that depleting local L-Try, an essential amino acid for T-cell proliferation, may block the cell cycle in the G1 phase and render T cells susceptible to proliferation arrest [12, 35, 36], and the other suggests that IDO may suppress T-cell responses by the action of Try metabolites, such as Kyn, which are…”
BackgroundLybaert, L., Vermaelen, K. Y., Geest, B. G. D., & Nuhn, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.009 · Cited by 54
Towards progress on DNA vaccines for cancer
Lowe, D. B., Shearer, M. H., Jumper, C., & Kennedy, R. C. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7165-0 · Cited by 49
Xu, Z., Hurchla, M. A., Deng, H., Uluçkan, Ö., Bu, F., Berdy, A., Eagleton, M. C., Heller, E., Floyd, D. H., Dirksen, W. P., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804812200 · Cited by 45
Coluccia, A., Passacantilli, S., Famiglini, V., Sabatino, M., Patsilinakos, A., Ragno, R., Mazzoccoli, C., Sisinni, L., Okuno, A., Takikawa, O., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00718 · Cited by 45
Glioma escape signature and clonal development under immune pressure
Maire, C. L., Mohme, M., Bockmayr, M. L., Fita, K. D., Riecken, K., Börnigen, D., Alawi, M., Failla, A. V., Kolbe, K., Zapf, S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138760 · Cited by 59
“IFN-γ, which is secreted by tumor-infiltrating T cells and NK cells, is known to play a dual role in cancer immunology (37, 38).”
BackgroundKondo, E., Gryschok, L., Klein-González, N., Rademacher, S., Weihrauch, M. R., Liebig, T. M., Shimabukuro‐Vornhagen, A., Kochanek, M., Draube, A., & von Bergwelt‐Baildon, M. S. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03820.x · Cited by 45
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
Ware, M. B., Phillips, M., McQuinn, C. W., Zaidi, M. Y., Knochelmann, H. M., Greene, E. R., Robinson, B. S., Herting, C. J., Mace, T. A., Chen, Z., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.155006 · Cited by 44
Dubrot, J., Palazón, A., Alfaro, C., Azpilikueta, A., Ochoa, M. C., Rouzaut, A., Martínez‐Forero, I., Teijeira, Á., Berraondo, P., Bon, A. L., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25333 · Cited by 44
“Involvement of Type I IFNs in immunosurveillance(18) against nascent chemically induced tumors has been experimentally described in mice.(19) Immunotherapy of cancer exploits these antitumor properties of IFN-a in an attempt to tackle already established malignancies.”
BackgroundCancer Immunosurveillance: NKG2D Breaks Cover
Ljunggren, H. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.007 · Cited by 44
“Overwhelming evidence now supports the concept of immune control of tumor development (Dunn et al., 2006; Hayakawa and Smyth, 2006).”
BackgroundPrediagnostic Immune Cell Profiles and Breast Cancer
Kresovich, J. K., O’Brien, K. M., Xu, Z., Weinberg, C. R., Sandler, D. P., & Taylor, J. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19536 · Cited by 45
Tseng, P., Chen, C., Lee, K.-Y., Feng, P., Wang, Y., Satria, R. D., & Lin, C. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215712 · Cited by 44
Lee, H., Deng, J., Xin, H., Liu, Y., Pardoll, D., & Yu, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3304 · Cited by 51
“3 Introduction The importance of our host immune system in both suppressing tumor incidence/growth and promoting malignant transformation has been well supported (1-4).”
Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta
Madar, S., Harel, E., Goldstein, I., Stein, Y., Kogan-Sakin, I., Kamer, I., Solomon, H., Dekel, E., Tal, P., Goldfinger, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061353 · Cited by 42
“non-responsive cells [19] or by contributing to oncogenic Ras”
BackgroundWan, Y., Chen, M., Li, X., Han, X., Zhong, L., Xiao, F., Liu, J., Xiang, J., Jiang, J., Chen, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216171 · Cited by 44
Methylation Patterns of the IFN-γ Gene in Cervical Cancer Tissues
Ma, D., Jiang, C., Hu, X., Liu, H., Li, Q., Li, T., Yang, Y., & Li, O. (2014) · Scientific Reports · doi:10.1038/srep06331 · Cited by 43
“Clin Cancer Res 17(19), 6118–6124 (2011).”
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer
Heppner, B. I., Loibl, S., & Denkert, C. (2016) · Breast Care · doi:10.1159/000444357 · Cited by 43
Nod1 Limits Colitis-Associated Tumorigenesis by Regulating IFN-γ Production
Zhan, Y., Seregin, S. S., Chen, J., & Chen, G. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501822 · Cited by 44
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
Castiello, L., Sestili, P., Schiavoni, G., Dattilo, R., Monque, D. M., Ciaffoni, F., Iezzi, M., Lamolinara, A., Sistigu, A., Moschella, F., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0675 · Cited by 43
“IFN-I signaling disruption impairs immunosurveillance therefore boosting tumor growth (38).”
BackgroundHomologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
Telli, M. L., Stover, D. G., Loi, S., Aparicio, S. A. J. R., Carey, L., Domchek, S. M., Newman, L. A., Sledge, G. W., & Winer, E. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4807-x · Cited by 47
Rubio, C., Munera-Maravilla, E., Lodewijk, I., Suárez-Cabrera, C., Karaivanova, V., Ruiz-Palomares, R., Paramio, J. M., & Dueñas, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1952-y · Cited by 47
Interface Oral Health Science 2014: Innovative Research on Biosis-Abiosis Intelligent Interface
Takahashi, N., Sasaki, K., & Takahashi, N. (2014) · Springer eBooks · doi:10.1007/978-4-431-55192-8 · Cited by 43
Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC
Brockwell, N. K., Rautela, J., Owen, K. L., Gearing, L. J., Deb, S., Harvey, K., Spurling, A., Zanker, D. J., Chan, C., Cumming, H. E., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0093-2 · Cited by 44
Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
Zulfiqar, B., Farooq, A. V., Kanwal, S., & Asghar, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1035171 · Cited by 44
“The phase II/III trials of this combination therapy are also in progress (Dunn et al., 2006).”
BackgroundInfluentialCancer immunotherapies: A hope for the uncurable?
Hamdan, F., & Cerullo, V. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140977 · Cited by 45
“These cells then enter the final stage of escape since they are unharmed by the immune system and can proliferate uncontrollably (Dunn et al., 2006; Kim et al., 2007; Swann and Smyth, 2007).”
BackgroundZhang, J., Luo, Q., Li, X., Guo, J., Zhu, Q. K., Lu, X., Wei, L., Xiang, Z., Peng, M., Ou, C., et al. (2023) · Biomarker Research · doi:10.1186/s40364-023-00530-4 · Cited by 43
“Interestingly, IFN-γ enhances the expression of MICA mRNA and protein levels in human corneal epithelial cells (HCECs) by down-regulating miRNA-4448, thereby enhancing cytotoxicity and HCEC apoptosis mediated by NK and CD8 + T cells on the corneal epithelium [45, 46].”
BackgroundImmunostimulation and Immunosuppression: Nanotechnology on the Brink
Fontana, F., Figueiredo, P., Bauleth‐Ramos, T., Correia, A., & Santos, H. A. (2018) · Small Methods · doi:10.1002/smtd.201700347 · Cited by 47
Wildes, T. J., Grippin, A., Dyson, K. A., Wummer, B. M., Damiani, D. J., Abraham, R. S., Flores, C. T., & Mitchell, D. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3061 · Cited by 44
“Given the impact ACT had on HSPC engraftment and gene signatures, and the appearance that IFNg was critical, we sought to verify the role of activated T-cell–released cytokines that drive HSPC differentiation (42,43).”
Awad, A. R., Youness, R. A., Ibrahim, M. M., Motaal, A. A. A., El‐Askary, H. I., Assal, R. A., & Gad, M. Z. (2019) · Natural Product Research · doi:10.1080/14786419.2019.1686372 · Cited by 42
“Stemming from the important role of the tumor microenvironment as well as immune cells infiltrates in BC (Aaltomaa and Lipponen 1992), immunotherapy emerged as a promising approach for BC patients, where the immune cells can recognize and eradicate BC cells (Dunn et al. 2006).”
BackgroundStudy of the antitumour effects and the modulation of immune response by histamine in breast cancer
Nicoud, M. B., Sterle, H., Massari, N. A., Delgado, M. A. T., Formoso, K., Ducloux, M. V. H., Lamas, D. J. M., Cremaschi, G., & Medina, V. A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0636-x · Cited by 44
Minimal Residual Disease, Metastasis and Immunity
Badia-Ramentol, J., Linares, J., Gómez‐Llonín, A., & Calon, A. (2021) · Biomolecules · doi:10.3390/biom11020130 · Cited by 44
Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics
Jindal, A., Sarkar, S., & Alam, A. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.629635 · Cited by 43
Systemic Interleukins’ Profile in Early and Advanced Colorectal Cancer
Czajka‐Francuz, P., Cisoń-Jurek, S., Czajka, A., Kozaczka, M., Wojnar, J., Chudek, J. T., & Francuz, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010124 · Cited by 42
Altered innate immunity in chronic hepatitis C infection: Cause or effect?
Szabó, G., Chang, S., & Dolganiuc, A. (2007) · Hepatology · doi:10.1002/hep.21938 · Cited by 43
Nam, S., & Park, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031685 · Cited by 43
“The recent literature [6,11,18,19,22,23,24] has set up a conceptual framework in which interactions between tumor and immunity are thought to help a number of cancer cells escape from immune-raiding by undergoing the following 3 phases in a linear or mixed manner: elimination (immunosurveillance), equilibrium (tumor d…”
BackgroundSchirrmacher, V. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1222 · Cited by 44
“In addition to their anti-viral functions, IFNs also have pleiotropic antitumor activity (20).”
BackgroundImmune Cell Recruitment and Cell-Based System for Cancer Therapy
Gao, J., Okada, N., Mayumi, T., & Nakagawa, S. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9443-9 · Cited by 49
Urosevic, M., Fujii, K., Calmels, B., Laine, E., Kobert, N., Acres, B., & Dummer, R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32077 · Cited by 48
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
Paillet, J., Plantureux, C., Lévesque, S., Le Naour, J., Stoll, G., Sauvat, A., Caudana, P., Tosello Boari, J., Bloy, N., Lachkar, S., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200853 · Cited by 41
“Intrigued by these observations, we decided to investigate the role of IL17a in PBCinduced anti-CCA immunosurveillance and compared IL17a with IFNγ, which is a well-established contributor to anticancer immune responses (Castro et al., 2018; Corthay et al., 2005; Dunn et al., 2006; Kalathil et al., 2019).”
BackgroundCo-evolution of glioma and immune microenvironment
Elguindy, M. M., Young, J. S., Ho, W. S., & Lu, R. O. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009175 · Cited by 42
Oncolysis by paramyxoviruses: preclinical and clinical studies
Matveeva, O. V., Guo, Z. S., Senin, V. M., Senina, A. V., Shabalina, S. A., & Chumakov, P. M. (2015) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2015.17 · Cited by 45
“During the malignant progression, cancer cells acquire mutations in different components of the IFN system, p53 and apoptotic pathways 32,36–39 that allow them to escape from the host regulation and to expand.”
Varikuti, S., Oghumu, S., Elbaz, M., Volpedo, G., Ahirwar, D. K., Alarcon, P. C., Sperling, R. H., Moretti, E., Pioso, M. S., Kimble, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1361088 · Cited by 41
“It has been largely thought that the control of tumor growth by STAT1 is mainly related to the ability to induce apoptosis and provide immunosurveillance of tumors.(44) Our data provide evidence of a new mechanism of how STAT1 can repress tumor”
BackgroundHuman Plasmacytoid Dendritic Cells and Cutaneous Melanoma
Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 43
Toda, Y., Kohashi, K., Yamada, Y., Yoshimoto, M., Ishihara, S., Ito, Y., Iwasaki, T., Yamamoto, H., Matsumoto, Y., Nakashima, Y., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03242-6 · Cited by 44
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.